CoreCap Advisors’s LENZ Therapeutics LENZ Stock Holding History

CoreCap Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-164	Closed	-$932	–	3384
2026 Q2	$932	Buy	+164	New	+$1.32K	﹤0.01%	2713
2025 Q4	–	Sell	-3,000	Closed	-$140K	–	3072
2025 Q3	$140K	Buy	+3,000	New	+$110K	0.01%	916
2025 Q2	–	Sell	-38	Closed	-$977	–	3297
2025 Q1	$977	Sell	38 -63	-62%	-$1.55K	﹤0.01%	2530
2024 Q4	$2.92K	Buy	+101	New	+$3.08K	﹤0.01%	2124

Other funds holding LENZ

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

CoreCap Advisors's LENZ Position: Q3 2026 in Review

CoreCap Advisors sold out of LENZ Therapeutics (LENZ) in Q3 2026, closing a stake of 164 shares — an estimated $932 sold.

CoreCap Advisors first reported a position in LENZ in Q4 2024 and held it in 4 quarters. The position peaked at $140K in Q3 2025. 4 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

CoreCap Advisors reported no remaining LENZ Therapeutics position as of Q3 2026 after selling out during the quarter.
CoreCap Advisors sold 164 LENZ Therapeutics shares in Q3 2026, an estimated $932.
CoreCap Advisors first reported a position in LENZ Therapeutics in Q4 2024 and held it in 4 quarters.
CoreCap Advisors's LENZ Therapeutics position peaked at $140K in Q3 2025.
4 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.